Ask about this productRelated genes to: SF3A2 antibody
- Gene:
- SF3A2 NIH gene
- Name:
- splicing factor 3a subunit 2
- Previous symbol:
- -
- Synonyms:
- SF3a66, SAP62, PRPF11, Prp11
- Chromosome:
- 19p13.3
- Locus Type:
- gene with protein product
- Date approved:
- 2000-02-29
- Date modifiied:
- 2015-11-09
Related products to: SF3A2 antibody
Related articles to: SF3A2 antibody
- To investigate the role of Sertoli cells in duck testicular development and maturation, we conducted single-cell RNA sequencing on testes from immature (IMT) and mature (MT) ducks. Sertoli cells accounted for 27.75 % and 33.42 % of testicular cells in IMT and MT, respectively. We identified 2,630 differentially expressed genes (DEGs) in mature Sertoli cells, with 1,540 upregulated and 1,090 downregulated. Subtype analysis revealed 2,498 DEGs in Sertoli cell type 1 (SC1) (898 up, 1,600 down) and 2,515 DEGs in SC2 (1,291 up, 1,224 down), including 1,090 SC1-specific, 1,107 SC2-specific, and 1,408 shared genes. Gene Ontology analysis showed DEGs were mainly linked to cellular components: SC1 DEGs were enriched in intracellular structures (e.g., nucleus), whereas SC2 DEGs were enriched in membrane- and extracellular-related components (e.g., cell periphery). KEGG pathway analysis highlighted significant enrichment of "Spliceosome," "Neurotrophin signaling," and "MAPK signaling" pathways in MT and IMT, with Neurotrophin signaling predominant in SC1 and MAPK signaling in SC2. Furthermore, the Notch signaling pathway was significantly enriched for SC1-specific genes, whereas the MAPK signaling pathway was significantly enriched for SC2-specific genes. Protein-protein interaction analysis of these pathways identified core genes, including SF3A2, SNRPF, SNRPB2, SNRPG, SF3B4, MAP3K1, NRAS, MET, and EGF. This study delineates developmental dynamics of duck Sertoli cells and offers preliminary insights into regulatory mechanisms underlying testicular maturation, providing a key theoretical and data-driven foundation for understanding Sertoli cell functions in avian testis development. - Source: PubMed
Publication date: 2026/04/29
Tao ZhiyunXu WenjuanSong WeitaoLu LizhiZhang ShuangjieLiu HongxiangWang ZhichengGu HaotianZhu ChunhongLi Huifang - Maternal obesity is known to adversely affect fetal development, with placental transcriptional dysregulation being one of the key mechanisms. However, the effect of a maternal high-fat diet (HFD) on dynamic placental gene expression, particularly in the context of obesity propensity, remains poorly understood. This study aimed to investigate the impact of a maternal HFD on time-dependent placental transcriptome alterations, with a focus on identifying key dysregulated pathways during mid-to-late gestation in rats. - Source: PubMed
Publication date: 2026/01/28
Du XiaohanWei YuchenLe ZhiyinWang HongliangChen ZhaoyangYu HuanlingCai Xiaxia - Splicing factor 3a subunit 2 (SF3A2) has been implicated in an increasing number of tumor types; however, at present, its role in clear cell renal cell carcinoma (ccRCC) has yet to be fully elucidated. Therefore, the aim of the present study was to preliminarily explore the putative function of SF3A2 in ccRCC. To meet this aim, SF3A2 expression in ccRCC tissues was analyzed using The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma dataset and conducted reverse transcription‑quantitative PCR, western blotting and immunohistochemical staining of ccRCC cell models to validate its functional roles. To evaluate the impact of SF3A2 expression on the proliferation, migration and invasion of ccRCC cells, Cell Counting Kit‑8 assays, colony formation assays, Transwell assays and an xenograft model were employed. Furthermore, western blot analysis was performed to explore which proteins may be involved in the underlying mechanisms of the effects of SF3A2 in ccRCC progression. SF3A2 was found to be markedly upregulated in ccRCC cells and tissues, and its high expression was associated with poor prognosis. The functional assays and experiments revealed that SF3A2 knockdown inhibited the proliferation, migration and invasion of the ccRCC cells, whereas its overexpression enhanced these processes. In terms of the underlying mechanism, SF3A2 was shown to promote ccRCC progression via activation of the AKT signaling pathway. In conclusion, the present study identified SF3A2 upregulation as a prognostic marker in ccRCC, which was associated with poor clinical outcomes and accelerated tumor progression. Mechanistically, SF3A2 exerted tumor‑promoting effects through the AKT signaling pathway. Taken together, these findings positioned SF3A2 as a dual‑functional biomarker with translational potential, facilitating prognostic stratification and presenting therapeutic targeting opportunities for ccRCC management. - Source: PubMed
Publication date: 2026/01/09
Chen RuXu Jie - Colorectal cancer (CRC) is one of the most prevalent malignancies globally and poses a substantial threat to human health. The current understanding of the biological significance of Splicing Factor 3a Subunit 2(SF3A2) in CRC remains limited. In this study, the upregulation of SF3A2 in CRC was identified through TMT-based quantitative proteomic screening of surgically resected paired primary cancer and normal epithelial tissues. Patients with elevated SF3A2 expression exhibited reduced survival compared to those with lower expression levels. Knockdown of SF3A2 significantly decreased cell proliferation, migration, and invasive properties both in vivo and in vitro. Bioinformatics enrichment analysis revealed that SF3A2 was involved in alternative splicing and functioned as an oncogene by modulating the expression of genes associated with critical tumorigenesis pathways and functions. Furthermore, immune infiltration analysis using multiple algorithms (including TIMER, EPIC, QUANTISEQ, and MCPCOUNTER) indicated an inverse relationship between SF3A2 expression levels and the presence of various immune cell types. Concurrently, predictions derived from the TIDE algorithm corroborated that patients exhibiting elevated SF3A2 expression were likely to experience a diminished response to immunotherapy. In summary, SF3A2 emerged as a promising therapeutic target for CRC and served as a novel biomarker for forecasting responses to immunotherapeutic interventions. - Source: PubMed
Publication date: 2026/01/01
Yang ChangjiangZhao ShidongZhao LongLin YuanpeiYe YingjiangWang CaihongShen Zhanlong - Serous ovarian cancer (SOC) is one of the most important diseases affecting women's health in the world. It is highly occult and often detected in late stage due to the lack of specific molecular markers. - Source: PubMed
Publication date: 2025/09/29
Zheng ChangtaoChen LuzhuLv XiaotianHe YaoyaoHu XiangyunDing YingWang ShengWei PengZhang TaoZhang HuainianZhang XiaotingZhang Yongli